Pegozafermin for Liver Cirrhosis
What You Need to Know Before You Apply
What is the purpose of this trial?
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking vitamin E at more than 400 IU per day, you must have been on a stable dose for at least 6 months before joining the trial.
Who Is on the Research Team?
Maya Margalit, MD
Principal Investigator
89bio, Inc.
Are You a Good Fit for This Trial?
Adults aged 18-75 with compensated cirrhosis due to MASH, confirmed by a liver biopsy showing stage F4 fibrosis. Participants must have a BMI of ≥25 (≥23 for Asians) and <50 kg/m² and at least one metabolic risk factor. Pregnant individuals or those not meeting the specific criteria are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pegozafermin or placebo for the duration of the study
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pegozafermin
Find a Clinic Near You
Who Is Running the Clinical Trial?
89bio, Inc.
Lead Sponsor